Sun Pharma will be able to manufacture and sell a limited quantity of generic lenalidomide capsules after March 2022, as well as an unlimited quantity beginning Jan. 31, 2026.
Lupin received approval for sevelamer hydrochloride tablets, which are indicated for the control of serum phosphorus in patients with chronic kidney disease on dialysis.